Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
US12059470B2 · kind B2 · utility
0Cited by
11References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 8, 2023 |
| Grant date | Aug 13, 2024 |
| Priority date | — |
| Expiry date | May 8, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.